Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 96.75 INR
Change Today +2.00 / 2.11%
Volume 9.4M
MRKS On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

marksans pharma ltd (MRKS) Snapshot

Open
95.35
Previous Close
94.75
Day High
98.90
Day Low
95.05
52 Week High
07/29/15 - 98.90
52 Week Low
08/8/14 - 31.05
Market Cap
39.6B
Average Volume 10 Days
5.4M
EPS TTM
2.74
Shares Outstanding
409.3M
EX-Date
--
P/E TM
35.3x
Dividend
0.12
Dividend Yield
0.10%
Current Stock Chart for MARKSANS PHARMA LTD (MRKS)

Related News

No related news articles were found.

marksans pharma ltd (MRKS) Related Businessweek News

No Related Businessweek News Found

marksans pharma ltd (MRKS) Details

Marksans Pharma Limited, together with its subsidiaries, is engaged in the research, manufacture, and marketing of generic pharmaceutical formulations worldwide. Its product portfolio covers primary therapeutic segments of CVS, analgesics, decongestants, gastrointestinal, cardiovascular, anti-diabetics, central nervous system, oncology, anti-allergic drugs, and others. It also manufactures and distributes over-the-counter pharmaceutical products in the areas of cough and cold remedies, galenicals, vitamins, palliative and healthcare items, oils, antiseptics, and disinfectants; and offers contract research and manufacturing services to global pharmaceutical companies. Marksans Pharma Limited is headquartered in Mumbai, India.

marksans pharma ltd (MRKS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

marksans pharma ltd (MRKS) Key Developments

Marksans Pharma Ltd. Recommends Dividend for the Financial Year Ended March 31, 2015

Marksans Pharma Ltd. announced that Board of Directors of the company has, at its meeting held on May 30, 2015, recommended dividend of INR 0.12 (rupees zero and paise twelve) that is 12% per equity share of INR 1 each face value for the financial year ended March 31, 2015, subject To Approve the shareholders in the upcoming Annual General Meeting.

Marksans Pharma Ltd. Reports Audited Standalone Earnings Results for the Fourth Quarter and Standalone and Consolidated Earnings Results for the Year Ended March 31, 2015

Marksans Pharma Ltd. reported audited standalone earnings results for the fourth quarter and standalone and consolidated earnings results for the year ended March 31, 2015. For the quarter, on standalone basis, the company reported net sales /income from operations of INR 91.738 million compared to INR 83.670 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 18.391 million compared to INR 11.612 million a year ago. Profit from ordinary activities before tax was INR 16.891 million against INR 8.140 million a year ago. Net profit for the period was INR 12.306 million or INR 0.30 per basic and diluted share before and after extraordinary items compared to INR 5.288 million or INR 0.14 per basic and diluted share before and after extraordinary items a year ago. For the year, on standalone basis, the company reported net sales /income from operations of INR 405.594 million compared to INR 314.945 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 109.798 million compared to INR 78.473 million a year ago. Profit from ordinary activities before tax was INR 96.685 million against INR 63.260 million a year ago. Net profit for the period was INR 67.109 million or INR 1.64 per basic and diluted share before and after extraordinary items compared to INR 55.558 million or INR 1.44 per basic and diluted share before and after extraordinary items a year ago. For the year, on consolidated basis, the company reported net sales /income from operations of INR 796.688 million compared to INR 629.997 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 171.929 million compared to INR 105.545 million a year ago. Profit from ordinary activities before tax was INR 155.884 million against INR 86.412 million a year ago. Net profit for the period was INR 111.963 million or INR 2.67 per basic and diluted share after extraordinary items compared to INR 73.625 million or INR 1.87 per basic and diluted share after extraordinary items a year ago.

Marksans Pharma Ltd., Board Meeting, May 30, 2015

Marksans Pharma Ltd., Board Meeting, May 30, 2015. Agenda: To consider and approve audited financial results of the company for the financial year ended March 31, 2015; and to consider recommendation of dividend, if any, for the financial year ended March 31, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRKS:IN 96.75 INR +2.00

MRKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MRKS.
View Industry Companies
 

Industry Analysis

MRKS

Industry Average

Valuation MRKS Industry Range
Price/Earnings 34.5x
Price/Sales 4.7x
Price/Book 10.3x
Price/Cash Flow 30.0x
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MARKSANS PHARMA LTD, please visit www.marksanspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.